Shopping Cart
- Remove All
- Your shopping cart is currently empty
Etalocib (LY293111) sodium is an orally active leukotriene B4 (LTB4) receptor antagonist with a Ki value of 25 nM for inhibiting [3H]LTB4 binding. It exhibits an IC50 of 20 nM against LTB4-induced calcium mobilization. Additionally, Etalocib sodium can induce apoptosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Etalocib (LY293111) sodium is an orally active leukotriene B4 (LTB4) receptor antagonist with a Ki value of 25 nM for inhibiting [3H]LTB4 binding. It exhibits an IC50 of 20 nM against LTB4-induced calcium mobilization. Additionally, Etalocib sodium can induce apoptosis. |
In vitro | Etalocib sodium exhibits concentration-dependent inhibition of LTB4-induced upregulation of CD11b. It acts as an extremely potent and selective antagonist of human neutrophil functions in vitro. Additionally, at concentrations of 250 and 500 nM over 24-72 hours, Etalocib sodium induces apoptosis and inhibits proliferation in human pancreatic cancer cells. |
In vivo | Etalocib demonstrates dose-dependent attenuation of acute leukotriene B4-induced airway obstruction, with an (ED 50 =14 μg/kg) when given intravenously and an (ED 50 =0.4 mg/kg) when administered orally. At a dosage of 10 mg/kg, it reduces lung inflammation induced by A23187 within one hour. Furthermore, daily oral administration of Etalocib at 250 mg/kg effectively suppresses the growth of human pancreatic cancer xenografts in athymic mice. |
Alias | LY293111 sodium |
Molecular Weight | 567.6 |
Formula | C33H33FNaO6 |
Cas No. | 152608-41-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.